ResearcherUniversitätsmedizin RostockActive in the last 2 years

Benjamin Schulz

Provisional: name at one institution (moderate confidence, 0.60), identity_conf@1As of 6 November 2026

Known by name at one institution; no external author ID yet. Sources: OpenAlex.

Their work

Papers: 3 (first author 1, last author 0)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 10

Papers, trials and grants by year

2022: 1 paper · 2023: none · 2024: 1 paper · 2025: 1 paper

Papers 3

Burrowing Behavior as Robust Parameter for Early Humane Endpoint Determination in Murine Models for Pancreatic Cancer. Co-author DOI 10.3390/ani15091241 ↗
Sex Matters-Insights from Testing Drug Efficacy in an Animal Model of Pancreatic Cancer. Co-author DOI 10.3390/cancers16101901 ↗
Inhibition of KRAS, MEK and PI3K Demonstrate Synergistic Anti-Tumor Effects in Pancreatic Ductal Adenocarcinoma Cell Lines. First author DOI 10.3390/cancers14184467 ↗

Closest collaborators

The 10 strongest of 10 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Dietmar Zechner · 3 shared papers, 2022–2025 · strength 0.59
Tim Schreiber · 2 shared papers, 2024–2025 · strength 0.45
- Paper Burrowing Behavior as Robust Parameter for Early Humane Endpoint Determination in Murine Models for Pancreatic Cancer. DOI 10.3390/ani15091241 ↗
- Paper Sex Matters-Insights from Testing Drug Efficacy in an Animal Model of Pancreatic Cancer. DOI 10.3390/cancers16101901 ↗
Brigitte Vollmar · 2 shared papers, 2024–2025 · strength 0.45
- Paper Burrowing Behavior as Robust Parameter for Early Humane Endpoint Determination in Murine Models for Pancreatic Cancer. DOI 10.3390/ani15091241 ↗
- Paper Sex Matters-Insights from Testing Drug Efficacy in an Animal Model of Pancreatic Cancer. DOI 10.3390/cancers16101901 ↗
Yixuan Ma · 2 shared papers, 2022–2024 · strength 0.33
- Paper Sex Matters-Insights from Testing Drug Efficacy in an Animal Model of Pancreatic Cancer. DOI 10.3390/cancers16101901 ↗
- Paper Inhibition of KRAS, MEK and PI3K Demonstrate Synergistic Anti-Tumor Effects in Pancreatic Ductal Adenocarcinoma Cell Li… DOI 10.3390/cancers14184467 ↗
Hugo Murua Escobar · 2 shared papers, 2022–2024 · strength 0.33
- Paper Sex Matters-Insights from Testing Drug Efficacy in an Animal Model of Pancreatic Cancer. DOI 10.3390/cancers16101901 ↗
- Paper Inhibition of KRAS, MEK and PI3K Demonstrate Synergistic Anti-Tumor Effects in Pancreatic Ductal Adenocarcinoma Cell Li… DOI 10.3390/cancers14184467 ↗
Jakob Brandstetter · 1 shared paper, 2025 · strength 0.26
- Paper Burrowing Behavior as Robust Parameter for Early Humane Endpoint Determination in Murine Models for Pancreatic Cancer. DOI 10.3390/ani15091241 ↗
Simone Kumstel · 1 shared paper, 2025 · strength 0.26
- Paper Burrowing Behavior as Robust Parameter for Early Humane Endpoint Determination in Murine Models for Pancreatic Cancer. DOI 10.3390/ani15091241 ↗
Robert Jaster · 1 shared paper, 2022 · strength 0.14
- Paper Inhibition of KRAS, MEK and PI3K Demonstrate Synergistic Anti-Tumor Effects in Pancreatic Ductal Adenocarcinoma Cell Li… DOI 10.3390/cancers14184467 ↗
Frank Ulrich Weiß · 1 shared paper, 2022 · strength 0.14
- Paper Inhibition of KRAS, MEK and PI3K Demonstrate Synergistic Anti-Tumor Effects in Pancreatic Ductal Adenocarcinoma Cell Li… DOI 10.3390/cancers14184467 ↗
Markus M. Lerch · 1 shared paper, 2022 · strength 0.14
- Paper Inhibition of KRAS, MEK and PI3K Demonstrate Synergistic Anti-Tumor Effects in Pancreatic Ductal Adenocarcinoma Cell Li… DOI 10.3390/cancers14184467 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.